The invention relates to novel compounds of the general formula (I), ##STR1## wherein R means hydrogen or a straight or branched chain C.sub.1-6 alkoxy group; R.sup.1 stands for hydrogen or a straight or branched chain C.sub.1-6 alkyl group; R.sup.2 represents hydrogen or a straight or branched chain C.sub.1-6 alkyl group; R.sup.3 means hydrogen, a straight or branched chain C.sub.1-6 alkyl group optionally substituted by one or two hydroxyl and/or one or two straight or branched chain C.sub.1-4 alkoxy group(s); or a C.sub.4-7 cycloalkyl group; R.sup.4 stands for hydrogen or a straight or branched chain C.sub.1-6 alkyl group optionally substituted by one or two hydroxyl and/or one or two straight or branched chain C.sub.1-4 alkoxy group(s); or a C.sub.4-7 cycloalkyl group; or R.sup.3 and R.sup.4 together with the nitrogen atom, to which they are attached form a 4 to 8-membered cyclic group of formula ##STR2## optionally substituted by one or two straight or branched chain C.sub.1-4 alkoxy and/or one or two straight or branched chain C.sub.1-4 alkyl group(s), where optionally an oxygen or sulfur atom or an N-R.sup.5 group may be substituted for a ring carbon atom, where R.sup.5 means hydrogen or a straight or branched chain C.sub.1-6 aliphatic alkyl group, the 4- to 8-membered cycle optionally being condensed with a benzene ring; R.sup.6 stands for hydrogen or a C.sub.1-10 acyl group and the salts and hydrates thereof as well as pharmaceutical compositions containing these compounds. The compounds of the invention antagonize the effects of constrictive mediators, e.g. histamine, acetylcholine or serotonin; they show an antiallergic action and possess an antiinflammatory effect. Thus, these compounds can therapeutically be used as bronchodilators as well as antiallergic or antiinflammatory drugs, particularly in the treatment of bronchial asthma.
本发明涉及一般式(I)的新化合物,其中R代表氢或直链或支链的C.sub.1-6烷氧基团;R.sup.1代表氢或直链或支链的C.sub.1-6烷基团;R.sup.2代表氢或直链或支链的C.sub.1-6烷基团;R.sup.3代表氢,一种直链或支链的C.sub.1-6烷基团,可选择地被一个或两个羟基和/或一个或两个直链或支链的C.sub.1-4烷氧基团取代;或C.sub.4-7环烷基团;R.sup.4代表氢或一种直链或支链的C.sub.1-6烷基团,可选择地被一个或两个羟基和/或一个或两个直链或支链的C.sub.1-4烷氧基团取代;或C.sub.4-7环烷基团;或R.sup.3和R.sup.4与它们连接的氮原子一起形成一个4到8个成员的环状基团,其
化学式为##STR2##可选择地被一个或两个直链或支链的C.sub.1-4烷氧基和/或一个或两个直链或支链的C.sub.1-4烷基团取代,其中可以用氧或
硫原子或N-R.sup.5基团替代环状碳原子,其中R.sup.5代表氢或直链或支链的C.sub.1-6脂肪基烷基团,4到8个成员的环状结构可选择地与苯环并置;R.sup.6代表氢或C.sub.1-10酰基团,以及这些化合物的盐和
水合物,以及含有这些化合物的药物组合物。本发明的化合物拮抗收缩介质(例如
组胺,
乙酰胆碱或
血清素)的作用;它们表现出抗过敏作用并具有抗炎作用。因此,这些化合物可以作为支气管扩张剂以及抗过敏或抗炎药物在治疗支气管哮喘方面得到治疗应用。